Molecule Details
| InChIKey | TVTXCJFHQKSQQM-LJQIRTBHSA-N |
|---|---|
| Canonical SMILES | COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Cross-Family |
| Avg pChEMBL | 8.14 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB12325 |
|---|---|
| Drug Name | Idasanutlin |
| CAS Number | 1229705-06-9 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Idasanutlin has been used in trials studying the treatment of Neoplasms, Non-Hodgkin's Lymphoma, Leukemia, Myeloid, Acute, Recurrent Plasma Cell Myeloma, and Neoplasms, Leukemia, Acute Myeloid Leukemia. |
Categories: Acids, Carbocyclic Aminobenzoates Benzene Derivatives Benzoates Proto-Oncogene Proteins c-mdm2, antagonists & inhibitors
Cross-references: BindingDB: 50437206 CHEMBL2402737 ChemSpider: 30831264 PubChem:53358942 PubChem:347828587 ZINC: ZINC000096273105